Back to search

Article

Remdesivir-Nirmatrelvir Combination: In Vitro Activity and a Case Report

2023-06-01

Abstract excerpt

<h4>Introduction: </h4> This study aims to investigate the activity of the remdesivir-nirmatrelvir combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and to report a case of Coronavirus Disease 2019 (COVID-19) cured with this combination. <h4>Methods:</h4> A Vero E6 cell-based infection assay was used to investigate the in vitro activity of the remdesivir-nirmatrelvir combination. The...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a549d86a-1619-5b6a-8d8b-b2e3da9d69ef
DOI
10.20944/preprints202306.0059.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Remdesivir-Nirmatrelvir Combination: In Vitro Activity and a Case ReportDOI 10.20944/preprints202306.0059.v1
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In VitroSemantic proximity
Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of ConcernSemantic proximity
Early combination with remdesivir, nirmatrelvir/ritonavir and sotrovimab for the treatment of COVID-19 in immunocompromised hostsSemantic proximity
Early combination with remdesivir, nirmatrelvir/ritonavir and sotrovimab for the treatment of COVID-19 in immunocompromised hostsSemantic proximity
The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replicationSemantic proximity
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected miceSemantic proximity
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single center studySemantic proximity
Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron SurgeSemantic proximity
Molnupiravir Compared to Nirmatrelvir/Ritonavir for COVID-19 in High-Risk Patients with Haematological Malignancy in Europe. A Matched-Paired Analysis from the Epicovideha RegistrySemantic proximity
Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivirSemantic proximity
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)Semantic proximity
Evaluating Drug Interaction Risks: Nirmatrelvir &amp; Ritonavir Combination (PAXLOVID®) with Concomitant Medications in Real-World Clinical SettingsSemantic proximity
Select a neighboring publication to make it the new centre.